Shandong-based China Biologic Products, a leading plasma-related pharmaceutical company in China, has announced that one of its research projects, "High-Purity Human Albumin," will be listed in the National Torch Plan of China.
The National Torch Plan was organized and executed in 1988, by China's Ministry of Science and Technology, to encourage innovation and promote the development of China's high-tech industry. Projects and enterprises listed in the plan have access to a series of support programs provided by the central and local government, including, favorable tax treatment, innovation protection, technical support, and a friendly business environment.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products China Biologic Products, is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.